Adverse events and costs among non-metastatic castration-resistant prostate cancer patients

References

• Key statistics for prostate cancer [Internet]. American Cancer Society; 2021 cited 2022 Feb 25]. Available from: https://www.cancer.org/cancer/prostate-cancer/about/key-statistics.html.
   Google Scholar
• Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7–33. doi: 10.3322/caac.21708.
   PubMed Web of Science ®Google Scholar
• SEER cancer stat facts: prostate cancer [Internet]. National Cancer Institute; [cited 2021 Aug 18]. Available from: https://seer.cancer.gov/statfacts/html/prost.html.
   Google Scholar
• Kirby M, Hirst C, Crawford ED. Characterising the castration-resistant prostate cancer population: a systematic review. Int J Clin Pract. 2011;65(11):1180–1192. doi: 10.1111/j.1742-1241.2011.02799.x.
   PubMed Web of Science ®Google Scholar
• Hotte SJ, Saad F. Current management of castrate-resistant prostate cancer. Curr Oncol. 2010;17 (Suppl 2):S72–S79. doi: 10.3747/co.v17i0.718.
   PubMed Web of Science ®Google Scholar
• Macomson B, Lin JH, Tunceli O, et al. Time to metastasis or death in non-metastatic castrate resistant prostate cancer (nmCRPC) patients by National Comprehensive Cancer Network (NCCN) risk groups. J Clin Oncol. 2017;35(15_suppl):5027–5027. doi: 10.1200/JCO.2017.35.15_suppl.5027.
   Google Scholar
• Smith MR, Saad F, Coleman R, et al. Denosumab and bone metastasis-free survival in men with castration-resistant prostate cancer: results of a global phase 3, randomized, placebo-controlled trial. Lancet. 2012;379(9810):39–46. doi: 10.1016/S0140-6736(11)61226-9.
   PubMed Web of Science ®Google Scholar
• Goldberg H. Expanding treatment options in non-metastatic castrate-resistant prostate cancer [Internet]. UroToday; January 22, 2022 [cited 2022 Feb 25]. Available from: https://www.urotoday.com/library-resources/mcrpc-treatment/114580-expanding-treatment-options-in-non-metastatic-castrate-resistant-prostate-cancer.html.
   Google Scholar
• Saad F, Bögemann M, Suzuki K, et al. Treatment of nonmetastatic castration-resistant prostate cancer: focus on second-generation androgen receptor inhibitors. Prostate Cancer Prostatic Dis. 2021;24(2):323–334. doi: 10.1038/s41391-020-00310-3.
   PubMed Web of Science ®Google Scholar
• Mottet N, van den Bergh RCN, Briers E, et al. EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer-2020 update. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol. 2021;79(2):243–262. doi: 10.1016/j.eururo.2020.09.042.
   PubMed Web of Science ®Google Scholar
• Smith MR, Saad F, Chowdhury S, et al. Apalutamide treatment and metastasis-free survival in prostate cancer. N Engl J Med. 2018;378(15):1408–1418. doi: 10.1056/NEJMoa1715546.
   PubMed Web of Science ®Google Scholar
• Smith MR, Saad F, Chowdhury S, et al. Apalutamide and overall survival in prostate cancer. Eur Urol. 2021;79(1):150–158. doi: 10.1016/j.eururo.2020.08.011.
   PubMed Web of Science ®Google Scholar
• Hussain M, Fizazi K, Saad F, et al. Enzalutamide in men with non-metastatic, castration-resistant prostate cancer. N Engl J Med. 2018;378(26):2465–2474. doi: 10.1056/NEJMoa1800536.
   PubMed Web of Science ®Google Scholar
• Sternberg CN, Fizazi K, Saad F, et al. Enzalutamide and survival in nonmetastatic, castration-resistant prostate cancer. N Engl J Med. 2020;382(23):2197–2206. doi: 10.1056/NEJMoa2003892.
   PubMed Web of Science ®Google Scholar
• Fizazi K, Shore N, Tammela TL, et al. Darolutamide in nonmetastatic, castration-resistant prostate cancer. N Engl J Med. 2019;380(13):1235–1246. doi: 10.1056/NEJMoa1815671.
   PubMed Web of Science ®Google Scholar
• Shah A, Shah R, Kebede N, et al. Real-world incidence and burden of adverse events among non-metastatic prostate cancer patients treated with secondary hormonal therapies for androgen deprivation therapy. J Med Econ. 2020;23(4):330–346. doi: 10.1080/13696998.2019.1705313.
   PubMed Web of Science ®Google Scholar
• Halabi S, Jiang S, Terasawa E, et al. Indirect comparison of darolutamide versus apalutamide and enzalutamide for nonmetastatic castration-resistant prostate cancer. J Urol. 2021;206(2):298–307. doi: 10.1097/JU.0000000000001767.
   PubMedGoogle Scholar
• Wang L, Paller C, Hong H, et al. Comparison of treatments for nonmetastatic castration-resistant prostate cancer: matching-adjusted indirect comparison and network meta-analysis. J Natl Cancer Inst. 2022;114(2):191–202. doi: 10.1093/jnci/djab071.
   PubMedGoogle Scholar
• Pilon D, Behl AS, Ellis LA, et al. Assessment of real-world Central nervous system events in patients with advanced prostate cancer using abiraterone acetate, bicalutamide, enzalutamide, or chemotherapy. Am Health Drug Benefits. 2017;10(3):143–153.
   PubMed Web of Science ®Google Scholar
• U.S. Bureau of Labor Statistics. CPI Home: U.S. Bureau of Labor Statistics. Bls.gov. Published 2023. https://www.bls.gov/cpi/.
   Google Scholar
• Hussain A, Jiang S, Varghese D, et al. Real-world burden of adverse events for apalutamide- or enzalutamide-treated non-metastatic castration-resistant prostate cancer patients in the United States. BMC Cancer. 2022;22(1):304. doi: 10.1186/s12885-022-09364-z.
   PubMed Web of Science ®Google Scholar